21.00NOK-3.23%Mkt Cap: 551.67M NOKP/E: —Last update: 2026-06-01
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap551.67M NOK
Enterprise Value521.06M NOK
Revenue (TTM)8.00K NOK
Gross Profit8.00K NOK
Net Income (TTM)-140.71M NOK
Revenue/Share0.0000 NOK
Last Price21.00 NOK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees15
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0013524942
Valuation
P/E (Trailing)—
P/E (Forward)-2.78
PEG—
EV/EBITDA-4.15
EV/Revenue65132.96
P/S71256.83
P/B6.64
EPS (TTM)-7.50
EPS (Forward)-7.80
52W Range
8.20446% of range35.80
52W High35.80 NOK
52W Low8.204 NOK
Profitability
Gross Margin100.00%
Oper. Margin-254312.50%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-46.84%
ROA-45.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-149.03M NOK
CapEx (TTM)359.00K NOK
FCF Margin-1186650.00%
FCF Yield-17.21%
Net Debt-48.99M NOK
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity0.00
Current Ratio6.70
Quick Ratio6.48
Book Value/Sh3.268 NOK
Cash/Share1.878 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 1, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.26.27M
Float11.68M
Insiders46.02%
Institutions14.67%
Technical
SMA 5021.62 (-2.9%)
SMA 20015.12 (+38.9%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)63.47K
Avg Vol (10d)14.62K
Technical Indicators
RSI (14)48.1
MACD0.0315
MACD Signal0.1536
MACD Hist.-0.1221
BB Upper23.11 NOK
BB Middle22.13 NOK
BB Lower21.14 NOK
BB Width8.91%
ATR (14)1.377 NOK
Vol Ratio (20d)0.20x